Prebensen, Christian
Lefol, Yohan
Myhre, Peder L.
Lüders, Torben
Jonassen, Christine
Blomfeldt, Anita
Omland, Torbjørn
Nilsen, Hilde
Berdal, Jan-Erik
Funding for this research was provided by:
Medisinske fakultet, Universitetet i Oslo
Eurostars (312005)
Helse Sør-Øst RHF
Article History
Received: 17 October 2022
Accepted: 24 June 2023
First Online: 26 June 2023
Change Date: 4 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-39872-2
Competing interests
: Biomarker reagents were provided free of charge by Roche Diagnostics. PM reports honoraria for serving on advisory boards, consulting and/or speaker fees from Amarin, AmGen, AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis and Novo Nordisk. TO has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, and SomaLogic via Akershus University Hospital, and speaker’s or consulting honoraria from Roche Diagnostics, Bayer and CardiNor. TO is also listed as an inventor on a patent application entitled: "GDF-15 for predicting the disease severity of a patient with COVID-19". All other authors report no potential conflicts of interest.